dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Planas Vilaseca, Alejandra |
dc.contributor.author | Simó Servat, Olga |
dc.contributor.author | Hernández Pascual, Cristina |
dc.contributor.author | Ortiz Zuñiga, Angel Michael |
dc.contributor.author | Herance Camacho, José Raul |
dc.contributor.author | Ferreira González, Ignacio |
dc.contributor.author | Simó Canonge, Rafael |
dc.contributor.author | Marsal Mora, Josep Ramon |
dc.date.accessioned | 2022-06-15T12:53:23Z |
dc.date.available | 2022-06-15T12:53:23Z |
dc.date.issued | 2021-12 |
dc.identifier.citation | Planas A, Simó-Servat O, Hernández C, Ortiz-Zúñiga Á, Marsal JR, Herance JR, et al. Diabetic Retinopathy and Skin Tissue Advanced Glycation End Products Are Biomarkers of Cardiovascular Events in Type 2 Diabetic Patients. J Pers Med. 2021 Dec;11(12):1344. |
dc.identifier.issn | 2075-4426 |
dc.identifier.uri | https://hdl.handle.net/11351/7689 |
dc.description | Cardiovascular disease biomarkers; Diabetic complications; Type 2 diabetes |
dc.description.abstract | Risk of cardiovascular events is not homogeneous in subjects with type 2 diabetes; therefore, its early identification remains a challenge to be met. The aim of this study is to evaluate whether the presence of diabetic retinopathy and accumulation of advanced glycation end-products in subcutaneous tissue can help identify patients at high risk of cardiovascular events. For this purpose, we conducted a prospective study (mean follow-up: 4.35 years) comprising 200 subjects with type 2 diabetes with no history of clinical cardiovascular disease and 60 non-diabetic controls matched by age and sex. The primary outcome was defined as the composite of myocardial infarction, coronary revascularization, stroke, lower limb amputation or cardiovascular death. The Cox proportional hazard multiple regression analysis was used to determine the independent predictors of cardiovascular events. The patients with type 2 diabetes had significantly more cardiovascular events than the non-diabetic subjects. Apart from the classic factors such as age, sex and coronary artery calcium score, we observed that the diabetic retinopathy and advanced glycation end-products in subcutaneous tissue were independent predictors of cardiovascular events. We conclude that the diabetic retinopathy and advanced glycation end-products in subcutaneous tissue could be useful biomarkers for selecting type 2 diabetic patients in whom the screening for cardiovascular disease should be prioritized, thereby creating more personalized and cost-effective medicine. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Journal of Personalized Medicine;11(12) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Retinopatia diabètica |
dc.subject | Glicosilació |
dc.subject | Cor - Malalties - Factors de risc |
dc.subject.mesh | Diabetic Retinopathy |
dc.subject.mesh | Glycation End Products, Advanced |
dc.subject.mesh | Cardiovascular Diseases |
dc.subject.mesh | /diagnosis |
dc.title | Diabetic Retinopathy and Skin Tissue Advanced Glycation End Products Are Biomarkers of Cardiovascular Events in Type 2 Diabetic Patients |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/jpm11121344 |
dc.subject.decs | retinopatía diabética |
dc.subject.decs | productos finales de la glicación avanzada |
dc.subject.decs | enfermedades cardiovasculares |
dc.subject.decs | /diagnóstico |
dc.relation.publishversion | https://doi.org/10.3390/jpm11121344 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Planas A, Simó-Servat O, Hernández C, Ortiz-Zúñiga Á, Simó R] Unitat de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spanish Institute of Health (ISCIII), 28029 Madrid, Spain. [Marsal JR, Ferreira-González I] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBER en Epidemiología y Salud Pública (CIBERESP), Spanish Institute of Health (ISCIII), 28029 Madrid, Spain. [Hernández C] Grup de Recerca en Imatge Molecular Mèdica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBBIM-Nanomedicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBERBBN, Spanish Institute of Health (ISCIII), 28029 Madrid, Spain |
dc.identifier.pmid | 34945815 |
dc.identifier.wos | 000738266800001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |